Finance

Lists
DBV:ETR
DBV Technologies SA
€2.35
0.00%
(0.00) 1D
Jul 23, 3:55:35 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for DBV...
Mkt. cap
685.32M
Avg. vol.
2.88K
Volume
0.00
52-wk high
€4.18
52-wk low
€1.50
EPS
-€0.63
No. of employees
170
Mkt. cap
685.32M
Avg. vol.
2.88K
Volume
0.00
52-wk high
€4.18
52-wk low
€1.50
EPS
-€0.63
No. of employees
170
News stories
From sources across the web
Profile
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
About DBV Technologies SA
CEO-
Employees170
FoundedMar 29, 2002
Headquarters-
SectorBiotechnology
Websitedbv-technologies.com
Last report
Jul 16, 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
-€0.10 / -€0.09
-11.98%miss
Revenue / Est. (EUR)
611.87K / 669.06K
-8.55%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.77M
645.00K
900.00K
700.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.62M
32.89M
33.40M
31.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.44M
12.80M
15.30M
20.10M
Operating expense
37.05M
45.70M
48.70M
51.30M
Total operating expenses
37.05M
45.70M
48.70M
51.30M
Operating income
-34.28M
-45.05M
-47.80M
-50.60M
Other non operating income
1.00K
-1.00K
-100.00K
-
EBT including unusual items
-33.16M
-44.46M
-47.40M
-50.20M
EBT excluding unusual items
-33.16M
-44.46M
-47.40M
-50.20M
Income tax expense
-
374.00K
200.00K
200.00K
Effective tax rate
-
-0.84%
-0.42%
-0.40%
Other operating expenses
-
-
-
-
Net income
-33.16M
-44.83M
-47.60M
-50.40M
Net profit margin
-1,195.53%
-6,950.23%
-5,288.89%
-7,200.00%
Earnings per share
-
-
-
-
Interest and investment income
1.11M
597.00K
500.00K
400.00K
Interest expense
-
-
-
-
Net interest expenses
1.11M
597.00K
500.00K
400.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.49M
-44.36M
-46.90M
-50.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer